Active Surveillance helps many men with low-risk prostate cancer avoid or delay treatment. But what if better testing could also help some men avoid an unnecessary biopsy and a low-risk cancer diagnosis in the first place? Join Jason M. Hafron, MD for a discussion of how blood and urine biomarkers, together with prostate MRI and other clinical information, may help doctors focus on cancers that deserve closer attention while reducing overdiagnosis. He’ll also explore what these evolving tools can and cannot yet tell men who are already on Active Surveillance. JOIN THE CONVERSATION The Goal Isn’t Finding More Prostate Cancer—It’s Finding the Right Prostate Cancer. Using precision diagnostics to reduce overdiagnosis and identify patients who truly need treatment. Saturday, November 21, 2026 · 12:00–1:30 p.m. Eastern / 9:00–10:30 a.m. Pacific This free ASPI meeting includes time for questions following the presentation. You can also send questions in advance to contactus@aspatients.org. REGISTER NOW WHAT WE’LL EXPLORE Why more diagnoses aren’t always better: How finding a low-risk cancer that might never cause harm can bring anxiety, repeated testing, and sometimes unnecessary treatment. Finding the cancers that matter: How blood and urine biomarkers, alongside MRI, may help guide decisions about who needs a biopsy, who might avoid one, and where uncertainty remains. What this means for Active Surveillance: Why deciding whether to biopsy is different from monitoring cancer after diagnosis, and why these newer tests cannot yet replace established surveillance follow-up. ASPI supports informed decisions made in partnership with patients’ healthcare teams. This discussion explores an evolving approach to diagnosis, while recognizing that decisions about testing, surveillance, and treatment depend on each person’s circumstances. ABOUT OUR SPEAKER Jason M. Hafron, MD Dr. Hafron is Chief Medical Officer and Medical Director of Clinical Research at the Michigan Institute of Urology and Professor of Urology at Oakland University’s William Beaumont School of Medicine. His clinical work includes prostate, kidney, and bladder cancer, and he has published and presented research at national and international scientific meetings. Saturday, November 21, 2026 · 12:00 p.m. Eastern / 9:00 a.m. Pacific REGISTER NOW
https://aspatients.org/event/prostate-cancer-overdiagnosis/